Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 6Breast Neoplasms 5Prostatic Neoplasms 4Melanoma 4Gliosarcoma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Childhood Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

Cetuximab 5Erlotinib Hydrochloride 3Radiotherapy 2Radiation 2Everolimus 2Docetaxel 2Cisplatin 2talactoferrin alfa 1mercaptoundecahydrododecaborate 1VTX-2337 1Taxes 1Sunitinib 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pharmacogenomic Testing 1Microarray Analysis 1Lenalidomide 1Immunohistochemistry 1Hydroxyurea 1Gene Expression Profiling 1Fluorouracil 1Electrophoresis, Polyacrylamide Gel 1Chemotherapy, Adjuvant 1Carboplatin 1CBLB502 1Biopsy 1Albumin-Bound Paclitaxel 14-boronophenylalanine-fructose 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tongue Neoplasms × Immunohistochemistry × Clear all
NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡